Sei Investments Co. Has $39.37 Million Stock Position in Natera, Inc. $NTRA

Key Points

• Sei Investments increased its Natera stake by 11.7% in the first quarter, purchasing 20,581 additional shares. Its 196,833 shares were valued at approximately $39.37 million, while institutional investors and hedge funds collectively owned 99.90% of Natera.
• Analyst sentiment remains positive, with Natera receiving a “Moderate Buy” consensus rating and an average price target of $267.83. Recent targets range from $245 to $310.
• Natera shares opened at $261.99, near the upper end of their 52-week range of $131.81 to $288.04. Insiders have sold 167,171 shares worth approximately $37.24 million over the past 90 days.

Sei Investments Co. lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 11.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 196,833 shares of the medical research company's stock after purchasing an additional 20,581 shares during the quarter. Sei Investments Co. owned about 0.14% of Natera worth $39,366,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in NTRA. Integrated Wealth Concepts LLC boosted its holdings in Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company's stock worth $221,000 after acquiring an additional 96 shares in the last quarter. NewEdge Advisors LLC increased its holdings in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company's stock valued at $644,000 after acquiring an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its position in shares of Natera by 8.6% during the first quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company's stock worth $847,000 after purchasing an additional 474 shares during the period. Sivia Capital Partners LLC acquired a new position in shares of Natera during the second quarter worth approximately $298,000. Finally, WINTON GROUP Ltd bought a new position in shares of Natera in the 2nd quarter worth $558,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts have commented on the stock. Wall Street Zen lowered shares of Natera from a "buy" rating to a "hold" rating in a research note on Saturday, May 9th. BTIG Research set a $275.00 price objective on shares of Natera and gave the company a "buy" rating in a report on Wednesday, June 24th. The Goldman Sachs Group initiated coverage on shares of Natera in a research report on Friday, June 5th. They set a "neutral" rating and a $245.00 target price for the company. Sanford C. Bernstein began coverage on shares of Natera in a research report on Friday, June 26th. They issued an "outperform" rating and a $310.00 price target on the stock. Finally, Royal Bank Of Canada started coverage on Natera in a research note on Thursday, June 11th. They set an "outperform" rating and a $275.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, Natera currently has an average rating of "Moderate Buy" and an average target price of $267.83.

Natera Price Performance

NTRA opened at $261.99 on Monday. The company's 50-day moving average is $240.75 and its 200 day moving average is $221.50. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $288.04. The firm has a market capitalization of $37.52 billion, a P/E ratio of -160.73 and a beta of 1.51.

Insider Activity

In related news, insider Solomon Moshkevich sold 3,405 shares of Natera stock in a transaction on Friday, May 1st. The stock was sold at an average price of $203.69, for a total transaction of $693,564.45. Following the sale, the insider directly owned 142,295 shares in the company, valued at approximately $28,984,068.55. This trade represents a 2.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Roelof Botha sold 78,000 shares of the company's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $220.31, for a total value of $17,184,180.00. Following the completion of the transaction, the director owned 1,076,198 shares of the company's stock, valued at $237,097,181.38. This trade represents a 6.76% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 167,171 shares of company stock worth $37,239,209. Corporate insiders own 5.05% of the company's stock.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.